| Jennifer Marcinkowski, | |
|
1415 E Kincaid St, Mount Vernon, WA 98274-4126 | |
| (360) 814-2184 | |
| Not Available |
| Full Name | Jennifer Marcinkowski |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1415 E Kincaid St, Mount Vernon, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760849046 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL60680384 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Marcinkowski, Po Box 1376, 1415 East Kincaid, Mount Vernon, WA 98273-1376 Ph: () - | Jennifer Marcinkowski, 1415 E Kincaid St, Mount Vernon, WA 98274-4126 Ph: (360) 814-2184 |
News Archive
Nearly 30 years since researchers first described HIV/AIDS, U.N. Secretary-General Ban Ki-moon on Thursday in Nairobi, Kenya, released a report assessing the global HIV/AIDS response, Agence France-Presse reports.
Two-thirds of all human embryos fail to develop successfully. Now, in a new study, researchers at the Stanford University School of Medicine have shown that they can predict with 93 percent certainty which fertilized eggs will make it to a critical developmental milestone and which will stall and die. The findings are important to the understanding of the fundamentals of human development at the earliest stages, which have largely remained a mystery despite the attention given to human embryonic stem cell research.
Detecting brain tumors at the earliest possible stage and eliminating them before seizures begin might be possible one day, according to research by scientists at Baylor College of Medicine and Texas Children's Hospital.
Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the first subject had been dosed in the Phase 1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2. The Phase 1 study is an open label ascending dose trial, assessing safety and immune response in healthy volunteers. The study is taking place in the UK at the Chelsea and Westminster Hospital in London and will involve up to 42 already identified subjects.
› Verified 2 days ago
Ms. Susan M Bengtson, MACCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 920 S 2nd St, Mount Vernon, WA 98273 Phone: 360-428-6141 | |
Alexandra Elizabeth Jordan, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 S 18th St, Mount Vernon, WA 98274 Phone: 360-424-1320 | |
Peggy Glass Paxton, MA CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 920 S 2nd St, Mount Vernon, WA 98273 Phone: 360-428-6141 | |
Crystal Conway, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 124 E Lawrence St, Mount Vernon, WA 98273 Phone: 360-428-6110 | |
Miss Sharlet Lee Jensen, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 320 Pacific Pl, Mount Vernon, WA 98273 Phone: 360-416-7570 Fax: 360-416-7580 | |
Samantha Kerry Lundell, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 S 18th St, Mount Vernon, WA 98274 Phone: 360-424-1320 | |
Ms. Melissa Colleen Murphy, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 320 Pacific Pl, Mount Vernon, WA 98273 Phone: 360-416-7570 |